What are Mission Vision & Core Values of Harrow Company?

What drives Harrow’s push to lead ophthalmic care?

In ophthalmic pharmaceuticals, Harrow shifted from compounding roots to a branded eye-care leader by mid-2025, focusing on regulatory rigor, strategic acquisitions, and patient-first innovation to capture a slice of a >$30 billion global market.

Harrow’s mission centers on accessible, high-quality eye therapies; its vision targets becoming the go-to partner for eye-care professionals; core values prioritize patient outcomes, regulatory compliance, and data-driven growth. Harrow Porter's Five Forces Analysis

Harrow Company mission focuses on innovation and affordability for ophthalmologists, optometrists and patients in the US, combining proprietary branded medications and high-quality compounded formulations to improve access and lower treatment costs.

Innovation-Led Care

Develops novel and compounded ophthalmic therapies to address surgical and chronic eye care gaps.

Affordability

Targets price-sensitive channels with competitive pricing and patient assistance to expand access.

Customer-Centric

Prioritizes healthcare professionals and patients, offering tailored compounded solutions via ImprimisRx.

Market Focus

Primarily serves the United States ophthalmic market with targeted commercial initiatives like VEVYE.

Hybrid Model

Combines proprietary branded drugs and customized compounding to differentiate from competitors.

Access & Outcomes

Measures success by increased formulary access, lower out-of-pocket costs and improved patient adherence.

Harrow Company mission emphasizes US-focused access, hybrid branded/compounded offerings and patient affordability, highlighted by the 2024–2025 commercial push for VEVYE and expanded ImprimisRx utilization; see Competitors Landscape of Harrow.

Complete Harrow Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Harrow Company vision is to be the premier ophthalmic pharmaceutical company in North America, driving innovation, accessibility, and customer success across surgical and dry-eye segments.

Market Leadership

Targeting dominance in North American ophthalmics through strategic acquisitions and focused portfolio growth.

Innovation

Investing in reformulations and clinical support to expand therapeutic impact and improve patient outcomes.

Accessibility

Keeping essential ophthalmic medicines available by revitalizing orphan or under-promoted brands.

Customer Success

Partnering with clinicians to ensure product adoption and surgical suite integration.

Scale & Integration

Full integration of the Novartis ophthalmic portfolio—ILEVRO, NEVANAC, VIGAMOX—expanded market reach and capabilities.

Growth Metrics

Early 2025 revenue growth around 40% year-over-year supports the trajectory toward market leadership.

By July 2025 Harrow manages a comprehensive ophthalmic portfolio and aims for U.S. surgical-suite saturation, focused on innovation, accessibility, and customer success. Read more: Mission, Vision & Core Values of Harrow

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Harrow Company core values shape internal culture and external conduct, aligning product innovation with clinical needs and affordability. These principles guide decision-making across manufacturing, sales, and patient-focused services.

Innovation in Clinical Solutions

Harrow prioritizes innovation across molecular discovery, delivery systems, and processes, exemplified by IHEEZO and its unique J-code reimbursement that improved office-based surgical efficiency.

Accessibility and Affordability

Using ImprimisRx and pricing strategies, Harrow maintained stable pricing through 2024–2025 for key ophthalmic compounded products, ensuring continued Medicare patient access to post-op care.

Integrity and Quality

Harrow adheres to CGMP standards with rigorous quality controls across manufacturing and outsourcing, distinguishing it from smaller compounding pharmacies and supporting large surgical centers.

Customer Success and Partnership

Harrow invests in professional education and consultative sales to help ophthalmology practices streamline supply chains and improve clinic economics, treating provider outcomes as its own success.

Explore how Harrow Company mission and Harrow Company vision influence strategic decisions and product roadmaps next—read the linked analysis on Growth Strategy of Harrow to continue.

Values: Harrow operates under core values that define culture and conduct, essential for trust in the medical community. Innovation: extends beyond molecules to delivery and reimbursement innovations like IHEEZO. Accessibility and Affordability: ImprimisRx stabilized ophthalmic pricing through 2024–2025. Integrity and Quality: CGMP compliance and rigorous QC across facilities. Customer Success: education and consultative sales drive practice-level outcomes.

Harrow Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Mission and vision statements shape Harrow Company’s strategic choices by setting priorities for product focus, M&A, and resource allocation. They translate high-level purpose into measurable actions that guide daily operations and long-term investments.

Mission, Vision & Core Values Overview

Clear mission and vision direct Harrow’s transformation into a focused ophthalmology leader.

• Mission: supply essential, often scarce ophthalmic products to stabilize market access
• Vision: be the premier North American provider of critical eye-care therapies
• Core values: patient-centricity, integrity, agility, accountability, collaboration
• Strategic effect: drives M&A, product relaunches, and portfolio concentration

Mission-Driven M&A

Acquisitions prioritize products that fill critical supply gaps and align with the mission.

Vision-Led Portfolio Focus

The vision to lead North America prompted exiting non-core lines to concentrate on ophthalmology.

Operational Priorities

Day-to-day decisions prioritize commercialization and supply reliability for high-need products.

Measurable Outcomes

Success is tracked via prescription volume, revenue run-rate, and market supply metrics.

Example: TRIESENCE Relaunch

The 2023–2024 acquisition and July 2025 relaunch of TRIESENCE addressed a confirmed market shortage.

Commercial Wins: VEVYE

VEVYE prescriptions rose by 150 percent between Q3 2024 and Q2 2025, reflecting mission-aligned commercialization.

The mission and vision have guided Harrow Company to focused M&A and product relaunches, producing a near-225 million dollars revenue run rate in H1 2025; read the next chapter: Core Improvements to Company's Mission and Vision and explore the company’s market approach via Target Market of Harrow

Influence: The mission and vision prompted the 2023–2024 TRIESENCE acquisition to solve shortages; by July 2025 the relaunch stabilized supply. Vision-driven focus on ophthalmology led Harrow to exit non-core businesses and prioritize key products, contributing to a near-225 million dollars H1 2025 run rate and a 150 percent increase in VEVYE prescriptions from Q3 2024 to Q2 2025.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE

Four focused improvements can strengthen Harrow Company mission and vision to match 2025 market realities and investor expectations. These enhancements aim to broaden geographic reach, integrate sustainability, accelerate digital-health adoption, and clarify measurable impact metrics.

Expand to a Global Health Perspective

Broaden Harrow Company vision to include emerging markets in Asia and Latin America, reflecting rising ophthalmic demand and aligning the Harrow Company mission with global sight-preservation efforts; this supports growth beyond North America where global ophthalmology markets are projected to grow at over 5% CAGR through 2028.

Embed Sustainable Innovation and ESG Targets

Incorporate 'sustainable innovation' into the Harrow Company values statement and mission to address plastic waste from single-use droppers and packaging, targeting measurable reductions in plastic use and carbon intensity to attract ESG-focused investors.

Integrate Digital Health and AI Commitments

Update the Harrow Company mission to commit to AI-driven diagnostics and digital therapeutics integration, reflecting 2025 industry shifts where AI adoption in ophthalmology exceeds 30% clinical usage in tier-1 clinics.

Set Clear, Measurable Impact Metrics

Define specific KPI targets in the Harrow Company corporate values and culture—such as market access in 10 new countries, 25% reduction in packaging waste, and 40% of product portfolio enabled by digital health within five years—to make the Harrow Company guiding principles operational.

Improvements: While Harrow Company mission and Harrow Company vision are robust, refine geographic scope to global markets and add sustainability and ESG goals; include digital-health integration as AI-driven diagnostics exceed clinical adoption thresholds by 2025. See Owners & Shareholders of Harrow for related governance context.